Thymosin-?_1 improving efficacy of Lamivudine treatment in patients with chronic hepatitis B
- VernacularTitle:胸腺肽?_1联合拉米夫定治疗慢性乙型肝炎
- Author:
Bingliang LIN
;
Guimei HUANG
;
Xiaohong ZHANG
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Thymosin-?_1;
Lamivudine
- From:
Chinese Journal of Infectious Diseases
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the long-term efficacy and safety profile of alpha-1-thymosin (T?_1) combined with Lamivudine(LAM) in the patients with chronic hepatitis B. Methods Eighty patients with chronic hepatitis B were randomly assigned by 1∶1 proportion to be given 100 mg LAM orally alone (LAM group) or T?_1 1.6 mg subcutaneous injection, combined with LAM(LAM+T?_1 group). Results 51.4 percent (18/35) of the patients achieved HBeAg seroconversion in combination group, while 5.4%(2/37) of the patients in LAM group achieved HBeAg seroconversion at 52 week, P
